Search
Amgen Inc
AMGNAdd to Watchlist
371.510USD
+5.460+1.49%
Close 07-23 16:00（ET）Quotes delayed by 15 min
200.17BMarket Cap
25.65P/E TTM
More Details of Amgen Inc Company
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Amgen Inc Info
Ticker SymbolAMGN
Company nameAmgen Inc
IPO dateJun 17, 1983
CEOBradway (Robert A)
Number of employees28000
Security typeOrdinary Share
Fiscal year-endJun 17
AddressOne Amgen Center Drive
CityTHOUSAND OAKS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91320-1799
Phone18054471000
Websitehttps://www.amgen.com/
Ticker SymbolAMGN
IPO dateJun 17, 1983
CEOBradway (Robert A)
Company Executives of Amgen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
645.95K
+0.51%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
75.13K
+0.59%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
48.67K
+1.91%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
12.07K
+2.25%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
8.02K
+8.29%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.93K
+1.30%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.10K
-18.98%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
4.11K
+16.18%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
3.82K
+17.39%
Ms. Mary E. Klotman
Ms. Mary E. Klotman
Independent Director
Independent Director
1.38K
+48.05%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
645.95K
+0.51%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
75.13K
+0.59%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
48.67K
+1.91%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
12.07K
+2.25%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
8.02K
+8.29%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.93K
+1.30%
FAQs
Who are the top five shareholders of Amgen Inc?
The top five shareholders of Amgen Inc are: Mr. Robert A. (Bob) Bradway
How many institutions hold shares of Amgen Inc (AMGN)?
As of 2026Q1, 4665 institutions hold shares of Amgen Inc, with a combined market value of approximately 460.83M, accounting for 85.38% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2252779.00.
What is the biggest source of revenue for Amgen Inc?
In 2026Q1, the Other products business generated the highest revenue for Amgen Inc, amounting to 7.26B and accounting for 19.76% of total revenue.